Celgene receives Approval from the CHMP for the Lenalidomide (Revlimid((R))) and Pomalidomide (Imnovid((R))) based Triplet Combination Therapies for the Treatment of Patients with multiple Myeloma-MedSci.cn

Celgene receives Approval from the CHMP for the Lenalidomide (Revlimid((R))) and Pomalidomide (Imnovid((R))) based Triplet Combination Therapies for the Treatment of Patients with multiple Myeloma

[Anonymous]

ONCOLOGY RESEARCH AND TREATMENT, 2019; 42 (5): 299

科室
- - 订阅+
  - 更多科室
工具
服务